The infographic summarizes the VIVA TRIAL as follows:
Year: 2024 Title: VIVA TRIAL Subtitle: Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus Type of Trial: A prospective, randomized, parallel, blinded trial
Objective: To compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and a small aortic annulus (SAA).
Participants: 151
Inclusion Criteria:
- At least 65 years of age
- Severe aortic stenosis and small aortic annulus
Exclusion Criteria:
- Aortic root dilatation (>45 mm)
- Chronic coronary artery disease not amenable to PCI or coronary artery bypass grafting
- Concomitant mitral or tricuspid valve disease or previous aortic valve surgery
Groups:
- TAVR (n = 77)
- SAVR (n = 74)
Primary Outcome:
- Impaired valve hemodynamics (defined as severe prosthesis-patient mismatch or moderate to severe aortic regurgitation) at 60 days %
- TAVR Group: 5.6%
- SAVR Group: 10.3%
- (P = 0.30)
Secondary Outcomes:
- Mortality at 30 days %
- TAVR Group: 1.3%
- SAVR Group: 1.4%
- (P = 1.00)
- Stroke at 30 days %
- TAVR Group: 0%
- SAVR Group: 2.7%
- (P = 0.24)
Conclusion: In patients with severe aortic stenosis and SAA (women in the majority), there was no evidence of superiority of contemporary TAVR versus SAVR in valve hemodynamic results. After a median follow-up of 2 years, there were no differences in clinical outcomes between groups.
Reference: Rodés-Cabau J et al. Circulation 2024;149:644-55